-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Warburg Research Reiterates "€42.00" Price Target for Fresenius Medical Care AG & Co. KGaA (ETR:FME)
Warburg Research Reiterates "€42.00" Price Target for Fresenius Medical Care AG & Co. KGaA (ETR:FME)
Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) has been given a €42.00 ($43.30) target price by investment analysts at Warburg Research in a report issued on Friday, Borsen Zeitung reports. Warburg Research's target price suggests a potential upside of 15.77% from the stock's previous close.
Other research analysts have also recently issued research reports about the stock. Jefferies Financial Group set a €64.00 ($65.98) price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, July 25th. UBS Group set a €38.00 ($39.18) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. set a €58.00 ($59.79) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. JPMorgan Chase & Co. set a €23.00 ($23.71) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a €37.00 ($38.14) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday.
Get Fresenius Medical Care AG & Co. KGaA alerts:Fresenius Medical Care AG & Co. KGaA Trading Down 0.3 %
FME stock traded down €0.10 ($0.10) during trading on Friday, hitting €36.28 ($37.40). The company had a trading volume of 645,041 shares, compared to its average volume of 704,197. The company has a quick ratio of 0.79, a current ratio of 1.26 and a debt-to-equity ratio of 91.78. The firm has a 50-day moving average price of €47.65 and a 200-day moving average price of €55.13. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €37.37 ($38.53) and a 12 month high of €69.96 ($72.12). The stock has a market cap of $10.63 billion and a price-to-earnings ratio of 12.09.
About Fresenius Medical Care AG & Co. KGaA
(Get Rating)Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- BJ's Wholesale Club Stock Has More Room to Grow
- 3 Hotel Stocks to Consider Checking into After Earnings
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) has been given a €42.00 ($43.30) target price by investment analysts at Warburg Research in a report issued on Friday, Borsen Zeitung reports. Warburg Research's target price suggests a potential upside of 15.77% from the stock's previous close.
據Borsen Zeitung報道,在週五發佈的一份報告中,華平研究的投資分析師給了Fresenius Medical Care AG&Co.KGaA(ETR:FME-GET評級)42.00歐元(43.30美元)的目標價。Warburg Research的目標價暗示,該股較前一交易日收盤價有15.77%的潛在上行空間。
Other research analysts have also recently issued research reports about the stock. Jefferies Financial Group set a €64.00 ($65.98) price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, July 25th. UBS Group set a €38.00 ($39.18) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. set a €58.00 ($59.79) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. JPMorgan Chase & Co. set a €23.00 ($23.71) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a €37.00 ($38.14) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday.
其他研究分析師最近也發佈了關於該股的研究報告。傑富瑞金融集團在7月25日星期一的一份研究報告中為費森尤斯醫療保健股份公司的股票設定了64.00歐元(65.98美元)的目標價。瑞銀集團在7月29日星期五的一份報告中為Fresenius Medical Care AG&Co.KGaA的股票設定了38.00歐元(39.18美元)的目標價。費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)在7月29日週五的一份報告中設定了58.00歐元(合59.79美元)的目標股價。摩根大通在7月29日週五的一份報告中為費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的股票設定了23.00歐元(23.71美元)的目標價。最後,德意志銀行Aktiengesellschaft在週二的一份報告中為Fresenius Medical Care AG&Co.KGaA的股票設定了37.00歐元(合38.14美元)的目標價。
Fresenius Medical Care AG & Co. KGaA Trading Down 0.3 %
費森尤斯醫療保健公司KGaA股價下跌0.3%
FME stock traded down €0.10 ($0.10) during trading on Friday, hitting €36.28 ($37.40). The company had a trading volume of 645,041 shares, compared to its average volume of 704,197. The company has a quick ratio of 0.79, a current ratio of 1.26 and a debt-to-equity ratio of 91.78. The firm has a 50-day moving average price of €47.65 and a 200-day moving average price of €55.13. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €37.37 ($38.53) and a 12 month high of €69.96 ($72.12). The stock has a market cap of $10.63 billion and a price-to-earnings ratio of 12.09.
FME股票在週五的交易中下跌0.10歐元(0.10美元),觸及36.28歐元(37.40美元)。該公司的成交量為645,041股,而其平均成交量為704,197股。該公司的速動比率為0.79,流動比率為1.26,債務權益比為91.78。該公司的50日移動均線價格為47.65歐元,200日移動均線價格為55.13歐元。Fresenius Medical Care AG&Co.KGaA的12個月低點為37.37歐元(38.53美元),12個月高位為69.96歐元(72.12美元)。該股市值為106.3億美元,市盈率為12.09倍。
About Fresenius Medical Care AG & Co. KGaA
關於費森尤斯醫療保健股份公司
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Fresenius Medical Care AG&Co KGaA在德國、北美和國際上提供透析護理和相關的透析護理服務。它通過門診透析診所網絡提供透析治療以及相關的實驗室和診斷服務;材料、培訓和患者支持服務,包括臨牀監測、後續援助和安排將用品運送到患者住所;以及根據合同向美國醫院提供為住院的終末期腎病(ESRD)患者和急性腎功能衰竭患者提供的透析服務。
See Also
另請參閲
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- BJ's Wholesale Club Stock Has More Room to Grow
- 3 Hotel Stocks to Consider Checking into After Earnings
- 克羅諾斯集團(Cronos Group Inc.)營收上升,是時候收購了嗎?
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望,而且它很便宜
- 北京批發俱樂部庫存有更大的增長空間
- 盈利後考慮登記的3家酒店股票
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
接受Fresenius Medical Care AG&Co.KGaA Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Fresenius Medical Care AG&Co.KGaA和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧